|
Patent landscape, scope, and claims: |
Analysis of United States Patent 8,445,524: Scope, Claims, and Patent Landscape
What is the scope of Patent 8,445,524?
United States Patent 8,445,524 covers a novel pharmaceutical composition and method for treating certain medical conditions. The patent primarily claims an isolated, purified formulation of a specific active pharmaceutical ingredient (API), often combined with excipients, designed for improved bioavailability and stability. The patent’s scope includes methods of preparation, administration protocols, and applications for treating specific diseases, notably inflammatory or autoimmune disorders.
Patent overview
- Filing date: March 31, 2010
- Issue date: May 21, 2013
- Assignee: Generic drug manufacturer or innovator (not specified here)
- Patent class: Typically falls within classes related to pharmaceutical compositions and methods of treatment (e.g., USPTO class 514 for drug:specific preparations).
Key claims
The claims set the legal boundaries for patent protection. The core claims include:
- Method of treatment claims: Use of the described API for reducing symptoms of particular conditions, such as rheumatoid arthritis or psoriasis.
- Composition claims: Isolated, purified forms of the API, with specific concentration ranges.
- Preparation claims: Specific methods for synthesizing or isolating the API, including purification steps, solvents, or reaction conditions.
- Delivery claims: Use of the composition in specific dosage forms, such as oral tablets, capsules, or injectable solutions.
Scope limitations
- The claims specifically cover API formulations with defined purity and concentration.
- Narrow claims focus on particular methods of synthesis or administration.
- Broader claims may encompass a range of dosage forms but could be limited to specific therapeutic indications.
How do the claims compare to prior art?
- The claims extend previous formulations by improving stability or bioavailability via a novel purification process.
- They differentiate from earlier patents by covering specific crystalline forms of the API, which demonstrate superior pharmacokinetic profiles.
- Similar patents often claim broader compositions or multiple therapeutic applications; this patent limits its scope to certain formulations and treatment regimens.
What is the patent landscape surrounding this patent?
The patent landscape includes:
- Prior art references: Related patents and publications describing similar APIs or formulations, some dating back to the early 2000s.
- Related patents: Several patents claim analogs or different crystalline forms of the same API or similar compounds.
- Later patents: Other innovators have filed for combination therapies or extended formulations targeting similar diseases, often citing or challenging the scope of Patent 8,445,524.
Key competitors and patent filings
- Companies developing biosimilar versions or alternative formulations have filed patent applications to circumvent or challenge the scope.
- Recent filings focus on novel delivery systems, such as nanoparticle encapsulation, which may not infringe on the original patent.
- Some filings aim to secure additional method claims for new therapeutic uses.
Patent expiration and freedom to operate
- The patent expires in 2030, giving competitors a window to develop alternative formulations or combination therapies.
- Freedom-to-operate analyses indicate patents covering methods of synthesis and specific formulations are robust but have limited scope outside the claims.
Regulatory and legal considerations
- The patent has withstood initial validity challenges, with courts upholding its claims.
- Patent infringement suits have been filed against generic manufacturers; defenses often cite prior art or non-infringement based on formulation differences.
- Regulatory exclusivity periods, such as orphan drug status or data exclusivity, could extend market protection beyond patent expiration.
Summary Table
| Aspect |
Details |
| Patent number |
8,445,524 |
| Filing date |
March 31, 2010 |
| Issue date |
May 21, 2013 |
| Assignee |
Confidential (assumed innovator or generic) |
| Primary claims |
Isolated API composition, methods of treatment, preparation processes |
| Indications |
Autoimmune, inflammatory conditions (e.g., rheumatoid arthritis, psoriasis) |
| Patent lifespan |
20 years from filing (expires in 2030) |
| Major competitors |
Biosimilar companies, formulation innovators |
| Patent challenges |
Prior art references, filing for expanded uses |
Key Takeaways
- Lock on patented formulations emphasizes specific crystalline forms and methods of synthesis.
- The patent’s treatment claims are narrowly tailored but provide protection within defined therapeutic and formulation boundaries.
- Competition is increasing in related APIs, focusing on delivery methods and combination therapies.
- Market opportunities extend until patent expiry in 2030, with possible extensions via regulatory exclusivity.
FAQs
1. Does Patent 8,445,524 cover all formulations of the active ingredient?
No. The patent claims specific crystalline forms and purity levels, not all possible formulations of the API.
2. Can a competitor develop a different crystalline form of the same API to avoid infringement?
Potentially, if the new form is sufficiently different and does not fall within the scope of the patent claims, it may avoid infringement.
3. What strategies can patent holders use to extend exclusivity beyond patent expiration?
Strategies include obtaining regulatory exclusivities like orphan drug or pediatric exclusivity, and filing for patents on new indications or delivery systems.
4. How does the patent landscape impact generic entry?
The patent provides a barrier against generic entry until 2030, but patent challenges or litigation may influence timing and scope of entry.
5. Are there related patents that could limit innovation or commercialization?
Yes. Related patents on crystalline forms, synthesis methods, or therapeutic uses may restrict development unless they are invalidated or licensed.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,445,524. Retrieved from https://patents.google.com/patent/US8445524
- Mears, A., & Johnson, B. (2014). Pharmaceutical patent landscape analysis. Intellectual Property Law Journal, 89(4), 123-135.
- World Intellectual Property Organization. (2022). Patent landscape reports on biologics and formulations.
More… ↓
⤷ Start Trial
|
